Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kindstar Globalgene Technology, Inc. ( (HK:9960) ) has provided an announcement.
Kindstar Globalgene Technology, Inc. has issued a profit warning, expecting to report a loss between RMB55 million and RMB65 million for the year ending December 31, 2024, compared to a profit of RMB36.4 million in the previous year. The anticipated losses are attributed to significant credit-impaired losses from prolonged accounts receivable cycles, economic downturn impacts, intensified industry competition, and strategic adjustments affecting net income. Despite these challenges, the company’s core business remains stable, projecting a net profit of RMB30 million to RMB35 million, excluding certain losses.
More about Kindstar Globalgene Technology, Inc.
Kindstar Globalgene Technology, Inc. operates in the medical testing industry, focusing on specialty esoteric testing as its core business. The company is actively exploring prospective areas within this field to enhance its market position.
YTD Price Performance: 20.34%
Average Trading Volume: 2,109,758
Technical Sentiment Consensus Rating: Hold
Current Market Cap: HK$1.44B
For a thorough assessment of 9960 stock, go to TipRanks’ Stock Analysis page.